GlassScriptPhysician profile
Amit Keith Correa
NPI 1710396486
$10,546.43
in general payments reported to CMS, 2019-2025
47 companies · $5,074 in 2025
The $5,074 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $99.48 · 2021: $914 · 2022: $580 · 2023: $1,090 · 2024: $2,533 · 2025: $5,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,748 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $1,439 · Consulting Fee: $1,250 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,748.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $1,439.24 |
| Consulting Fee | $1,250.00 |
| Education | $259.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avyxa Pharma, LLC | $3,734.76 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $1,268.18 | 2019-2025 | Imfinzi, Lynparza, Enhertu |
| Celgene Corporation | $897.54 | 2019-2025 | Reblozyl, Pomalyst, Onureg |
| Beigene USA, INC. | $569.07 | 2023-2024 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $507.20 | 2021-2025 | Reblozyl, Opdualag, Opdivo |
| Seagen INC. | $375.97 | 2021-2025 | Adcetris, Padcev |
| Pfizer INC. | $311.34 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $234.47 | 2020-2022 | |
| Sobi, INC | $217.96 | 2024 | |
| Blueprint Medicines Corporation | $151.29 | 2022 | |
| Gilead Sciences, INC. | $141.08 | 2023-2025 | Trodelvy |
| Genentech USA, INC. | $129.12 | 2023 | Tecentriq |
| Astellas Pharma US INC | $116.71 | 2024 | Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $114.28 | 2022 | |
| Janssen Biotech, INC. | $112.11 | 2022-2025 | Darzalex, Talvey, Tecvayli |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $110.30 | 2024-2025 | Zejula, Jemperli, Ojjaara |
| Amgen INC. | $110.08 | 2022 | |
| Acrotech Biopharma INC. | $103.80 | 2022 | |
| Dova Pharmaceuticals | $100.22 | 2021 | |
| Pharmacosmos Therapeutics INC. | $99.50 | 2021 | |
| Lilly USA, LLC | $94.71 | 2021-2025 | Jaypirca, Verzenio |
| Pharmaessentia USA Corporation | $93.74 | 2024-2025 | Besremi |
| Alexion Pharmaceuticals, INC. | $92.17 | 2023 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.38 | 2019 | |
| Merck Sharp & Dohme LLC | $87.73 | 2024-2025 | Keytruda, Lynparza |
| Syndax Pharmaceuticals, INC. | $72.81 | 2025 | |
| Genzyme Corporation | $63.03 | 2022-2025 | |
| Tempus Ai, INC | $58.93 | 2024-2025 | Xt Cdx |
| Novartis Pharmaceuticals Corporation | $54.62 | 2023-2025 | |
| Daiichi Sankyo INC. | $43.31 | 2025 | Datroway |
| Adaptive Biotechnologies Corporation | $41.73 | 2024-2025 | Clonoseq |
| Boston Scientific Corporation | $39.79 | 2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Deciphera Pharmaceuticals INC. | $36.33 | 2024-2025 | Qinlock, Romvimza, Tgct |
| Abbvie INC. | $31.44 | 2024 | |
| Tersera Therapeutics LLC | $23.47 | 2025 | Xermelo |
| Incyte Corporation | $23.09 | 2023 | Monjuvi |
| Csl Behring | $21.12 | 2021 | |
| Beone Medicines USA, INC. | $20.59 | 2025 | Brukinsa |
| Mirati Therapeutics, INC. | $19.23 | 2023 | Krazati |
| Spectrum Pharmaceuticals INC. | $18.44 | 2025 | Rolvedon |
| Servier Pharmaceuticals LLC | $18.07 | 2022 | |
| Genmab U.S., INC. | $18.01 | 2025 | Epkinly |
| Recordati_rare_diseases_inc. | $17.12 | 2025 | Enjaymo |
| Nuvation Bio INC. | $16.65 | 2025 | Ibtrozi |
| Legend Biotech USA INC. | $15.99 | 2025 | Carvykti |
| Taiho Oncology, INC. | $14.69 | 2024 | |
| Coherus Oncology, INC. | $13.26 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Correa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.